Literature DB >> 23277116

Successful liver transplantation in a patient with splanchnic vein thrombosis and pulmonary embolism due to polycythemia vera with Jak2v617f mutation and heparin-induced thrombocytopenia.

Emanuela Biagioni1, Paola Pedrazzi, Marco Marietta, Fabrizio Di Benedetto, Erica Villa, Mario Luppi, Massimo Girardis.   

Abstract

Heparin-induced thrombocytopenia (HIT) is a rare complication of heparin treatment resulting in a severe acquired thrombophilic condition with an associated mortality of about 10 %. We report the first case of successful urgent liver transplantation (LT) in a patient with end-stage liver disease due to a Budd-Chiari syndrome, portal vein thrombosis and pulmonary embolism due to acquired thrombophilia associated to polycythemia vera carrying JAK2V617F gene mutation and HIT in the acute phase. Lepirudin was used to provide anticoagulation in the LT perioperative period that was performed without haemorrhagic and thrombotic complications despite the donor received heparin during liver explantation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23277116     DOI: 10.1007/s11239-012-0832-5

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  7 in total

Review 1.  Splanchnic vein thrombosis: clinical presentation, risk factors and treatment.

Authors:  Valerio De Stefano; Ida Martinelli
Journal:  Intern Emerg Med       Date:  2010-06-08       Impact factor: 3.397

Review 2.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Donor heparinization is not a contraindication to liver transplantation even in recipients with acute heparin-induced thrombocytopenia type II: a case report and review of the literature.

Authors:  R Bachmann; S Nadalin; J Li; J Lange; R Ladurner; A Königsrainer; A Heininger
Journal:  Transpl Int       Date:  2011-09-02       Impact factor: 3.782

Review 4.  Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.

Authors:  Ayalew Tefferi
Journal:  Am J Hematol       Date:  2012-03       Impact factor: 10.047

5.  Management of liver transplantation in a patient with a history of heparin-induced thrombocytopenia.

Authors:  Reinhold Fretschner; Klaus Dietrich; Klaus Unertl; Andreas Greinacher
Journal:  Transpl Int       Date:  2005-06       Impact factor: 3.782

6.  JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis.

Authors:  Francesco Dentali; Alessandro Squizzato; Lorenza Brivio; Lorena Appio; Leonardo Campiotti; Mark Crowther; Anna Maria Grandi; Walter Ageno
Journal:  Blood       Date:  2009-03-09       Impact factor: 22.113

7.  A report of outcomes after orthotopic liver transplant with allografts from heparin antibody-positive donors.

Authors:  Thomas A Aloia; John A Goss
Journal:  Exp Clin Transplant       Date:  2009-03       Impact factor: 0.945

  7 in total
  3 in total

Review 1.  Heparin-induced thrombocytopenia in solid organ transplant recipients: The current scientific knowledge.

Authors:  Volker Assfalg; Norbert Hüser
Journal:  World J Transplant       Date:  2016-03-24

2.  Heparin-induced thrombocytopenia associated with polycythemia vera during the treatment of acute coronary syndrome.

Authors:  Takashi Yoshizane; Makoto Iwama; Takahiro Ueno; Maya Ishiguro; Yoshiaki Goto; Koji Ono; Masazumi Arai; Toshiyuki Noda
Journal:  J Cardiol Cases       Date:  2016-04-28

3.  Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera.

Authors:  Sara C Meyer; Eva Steinmann; Thomas Lehmann; Patricia Muesser; Jakob R Passweg; Radek C Skoda; Dimitrios A Tsakiris
Journal:  Biomed Res Int       Date:  2017-06-18       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.